BRAF and cancer: By inclusion of a smMIP targeting BRAF in the assay, these 14 samples were found to have c.1799T>A variant allele frequencies (VAFs) >5%, a threshold generally considered to be clinically relevant in cancer diagnostics (Jennings et al., 2017).